However, BCL11B is often aberrantly activated due to structural variations that put BCL11B under the control of enhancers active in HSPCs or early precursors, which effectively results in the overexpression of BCL11B in MPAL or ETP-ALL [47]. The gene discussed is BCL11B; the disease is acute lymphoblastic leukemia.